Last reviewed · How we verify
Rosiglitazone/alpha-lipoic acid
Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while alpha-lipoic acid acts as an antioxidant to reduce oxidative stress and improve glucose metabolism.
Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while alpha-lipoic acid acts as an antioxidant to reduce oxidative stress and improve glucose metabolism. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Rosiglitazone/alpha-lipoic acid |
|---|---|
| Also known as | Avandia/Thioctic acid |
| Sponsor | Seoul St. Mary's Hospital |
| Drug class | Thiazolidinedione + antioxidant combination |
| Target | PPAR-γ (rosiglitazone); mitochondrial oxidative stress (alpha-lipoic acid) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Rosiglitazone is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. Alpha-lipoic acid is a naturally occurring antioxidant that may improve mitochondrial function and glucose utilization. The combination is intended to provide complementary metabolic benefits for glycemic control and potentially reduce insulin resistance through dual mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia
- Gastrointestinal upset
Key clinical trials
- Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes (PHASE4)
- Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosiglitazone/alpha-lipoic acid CI brief — competitive landscape report
- Rosiglitazone/alpha-lipoic acid updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI